CANCER NEWS SOURCE

• share
• favorite_border

A new study(Link is external) (Link opens in new window) led by a UCLA-VA collaborative team looking at the landscape of genomic alterations in more than 5,000 veterans with metastatic prostate cancer uncovered differences in the genomic makeup of cancer cells that were associated with race and ethnicity.

• share
• favorite_border

A study led by UCLA Health Jonsson Comprehensive Cancer Center(Link opens in new window) researchers found that using a combination of experimental immunotherapy drugs with chemotherapy significantly improves progression-free survival and overall survival for patients with metastatic colorectal cancer who have previously undergone standard chemotherapy treatment when compared to those who received the targeted therapy regorafenib alone.

• share
• favorite_border

May 22nd marked a significant milestone in the collaborative efforts to combat ovarian cancer as the "International Dialogue on Ovarian Cancer, from Bench to Bedside" congress was held, bridging the gap between primary research and clinical practice.

• share
• favorite_border

ASCO: Treatment options for multiple myeloma are shifting rapidly, with new patients increasingly being treated with a 4-part drug combination that includes a new immunotherapy agent. What does this mean for patients, and how will treatment change in the future?

• share
• favorite_border

Clinicians and scientists from Rutgers Cancer Institute and RWJBarnabas Health will lead sessions and present their latest discoveries from their innovative cancer research program at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held in Chicago (and online) from May 30-June 4.

• share
• favorite_border

Researchers from Penn Medicine’s Abramson Cancer Center (ACC) and the Perelman School of Medicine at the University of Pennsylvania will present data on the latest advances in cancer research at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, happening May 31—June 4, 2024 in Chicago and online.

• share
• favorite_border

New research by Dana-Farber Cancer Institute investigators has encouraging news for young women who have survived breast cancer and want to have children.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. This special edition features presentations by MD Anderson researchers at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

• share
• favorite_border

In 2022, collegiate volleyball player Sina Sinbari's back pain led to a rare cancer diagnosis. He sought treatment at UCLA Health, balancing rigorous chemo and radiation with volleyball training. Despite setbacks, including the loss of a young friend, he returned to school in 2024, embracing gratitude and resilience.

• share
• favorite_border

The American Society for Radiation Oncology (ASTRO) published an updated clinical guideline that details best practices for treating patients who have symptomatic bone metastases and ways to improve their quality of life. The guideline is available as a free access article in Practical Radiation Oncology. “Radiation therapy is a cornerstone of care for patients with symptomatic bone metastases, offering a nonsurgical option for fast pain relief and improved quality of life with minimal side effects,” said Tracy Balboni, MD, MPH, chair of the guideline task force.

• share
• favorite_border

• share
• favorite_border

ASCO, the largest event in cancer research, is approaching on May 31st. This year's meeting promises to be particularly groundbreaking, with new findings and innovations that could revolutionize cancer treatment.

• share
• favorite_border

The U.S. Food and Drug Administration recently approved two new wound management products that include patented hydrogels invented by University of Delaware researchers. The unique UD hydrogel materials self-assemble to form a 3D matrix compatible with living cells.

• share
• favorite_border

Location, race and insurance status play a significant part in the odds of a patient being diagnosed with early-stage or late-stage cancer, according to a detailed medical records analysis of more than 94,000 patients with cancer by researchers at the Johns Hopkins Bloomberg School of Public Health and the Johns Hopkins Kimmel Cancer Center.

• share
• favorite_border

Lucy, with her boundless puppy-like energy even at 12 years old, is more than just a pet to Susan Ketcham. She's now part of a research project that could transform the way we treat brain cancer – in both dogs and humans. This study at Virginia Tech's Virginia-Maryland College of Veterinary Medicine explores an innovative therapy called histotripsy.

• share
• favorite_border

The number of mutations in the DNA of cancerous tumors may not be an indicator of how well patients will respond to immune checkpoint inhibitors (ICIs), a commonly prescribed type of immunotherapy, a team led by UT Southwestern Medical Center researchers reported in a retrospective study. The findings, published in Nature Cancer, upend long-held conventional wisdom and could lead to more effective ways of deciding which patients will benefit most from this type of treatment.

• share
• favorite_border

A team of researchers led by Associate Professor Alfredo Franco-Obregón from the NUS Institute for Health Innovation & Technology (iHealthtech) has unveiled a novel approach to stimulate muscle, by way of using brief and mild pulsed electromagnetic field exposure, to produce and release proteins possessing anticancer properties.

• share
• favorite_border

An FDA committee voted unanimously last month to approve a new clinical endpoint, minimal residual disease, when evaluating proposed drugs to treat multiple myeloma. The 12-0 vote was based primarily on an analysis spearheaded by C. Ola Landgren, M.D., Ph.D., first author of a new paper published May 20 in the journal Blood.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.